Forma Therapeutics, whose investors include Eli Lilly and Novartis, has closed its IPO after seeing its shares double in price.

Forma Therapeutics, a US-based cancer and haematologic disease therapy developer backed by pharmaceutical firms Novartis and Eli Lilly, completed a $319m initial public offering yesterday. The company went public last Friday, expanding the size of the IPO from 11.8 million to 13.9 million shares and pricing them above the range at $20 each. Its shares…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.